Biometrics: Receives

Showing posts with label Receives. Show all posts

FST Biometrics Receives Lenel Factory Certification Under Lenel's OpenAccess Alliance Program

Sorry, I could not read the content fromt this page.

IBM Receives Frost & Sullivan Customer Value Leadership Award for its Mobile Identity and Access Management Solutions

MOUNTAIN VIEW, Calif., May 20, 2014 /PRNewswire/ -- Based on its recent analysis of mobile authentication, Frost & Sullivan recognizes IBM with the 2014 Global Frost & Sullivan Award for Customer Value Leadership. Central to the company's success in generating value for customers is the integration of various mobile security, mobile identity, and access management solutions. IBM's strong value proposition with regards to the provisioning of context-based authentication for multiple mobile device types and mobile applications has also been instrumental to its success.

"When it comes to identity and access management, organizations often face a trade-off between improving security levels and delivering greater end-user convenience," said Frost & Sullivan Senior Industry Analyst Mario Fernandez. "IBM breaks the security/end-user convenience trade-off through its IBM Security Access Manager for Mobile appliance."

The IBM Security Access Manager for Mobile appliance's risk engine determines the risk of an end user's authentication attempt by comparing it with a historical behavior profile of that user, which contains information related to the volume, type and frequency of transactions; Internet protocol reputation; geographic location; and device fingerprinting. On ascertaining the risk, the appropriate authentication method is applied. While low-risk access attempts require simple authentication methods such as a password, high-risk access attempts might involve hardware or software one-time password tokens.

To determine the appropriate authentication method, the IBM Security Access Manager for Mobile risk engine also pays heed to the application or data that the end user wants to access. For instance, if an end user wants to access a business-critical application or confidential data, then they must use an authentication method with a high degree of irrefutability. Essentially then, security becomes context-based and organizations can establish—and seamlessly enforce—access management policies without introducing greater end-user inconvenience.

The value proposition of IBM's Security Access Manager for Mobile appliance is enhanced through the integration of other IBM products, including IBM Security Access Manager for Web, which adds content security capabilities to protect against attacks such as SQL injection and cross-site scripting. Likewise, IBM's Federated Identity Manager, which supports the Security Assertion Markup Language (SAML), WS-Federation and OpenID standard protocols, can enable federated single sign-on. This facilitates the integration of cloud services, such as Google Apps or Office 365, which also support the above-mentioned protocols.

In a bid to remain ahead of its competitors, IBM added two important security companies and their corresponding products to its portfolio in 2013—Trusteer and Fiberlink. The company has also drawn up a future-proof product roadmap that recognizes that biometric authentication methods and contactless technologies will play a prominent role in enabling mobile access.

"Already, IBM's scientists have developed an algorithm to determine biometric-based authentication risk scores and risk analysis that can be incorporated into IBM Security Access Manager for Mobile," said Fernandez.

Each year, Frost & Sullivan presents this award to the company that demonstrates excellence in implementing strategies that proactively create value for its customers with a focus on improving the return on the investment that customers make in its services or products. This award recognizes the company's inordinate focus on enhancing the value that its customers receive, beyond simply good customer service, leading to improved customer retention and, ultimately, customer base expansion.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research to identify best practices in the industry.

About IBM Security

IBM Security offers one of the most advanced and integrated portfolios of enterprise security products and services. The portfolio, supported by world-renowned IBM X-Force research and development, provides the security intelligence to help organizations protect their people, data, applications and infrastructure. IBM offers security solutions for identity and access management, database security, application development, risk management, endpoint management, next-generation intrusion protection and more. IBM operates one of the world's broadest security research and development, and delivery organizations. IBM monitors 15 billion security events per day in more than 130 countries and holds more than 3,000 security patents. For more information on IBM security solutions, X-Force reports, and webinars, please visit: www.ibm.com/security.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies? Contact us: Start the discussion.

Contact:

Mireya Espinoza
P: 210. 247.3870
F: 210.348.1003
E: mireya.espinoza@frost.com

Jacqueline McCouat
P: + 44 7768 504084
E: jacqueline.mccouat@uk.ibm.com

SOURCE Frost & Sullivan

FPC Receives Ramp Order of SEK 18M for FPC 1020 Touch Sensor for Tier 1 Flagship Smartphone DW

GOTHENBURG, Sweden, May 5, 2014 /PRNewswire/ --

In December 2013, Fingerprint Cards (FPC) announced the first design win (DW) for its new mobile touch sensor FPC1020 with a Global Tier 1 OEM for a flagship model with a targeted launch date in the summer of 2014. On April 14, FPC announced an initial pre-ramp purchase order worth SEK 4 M for the FPC 1020, for delivery in May 2014. Now, FPC has received the first ramp order of SEK 18 M for the production ramp in May-June 2014. During 2014, FPC expects to ship +3M units for this first flagship device alone.

Johan Carlstr?m, President and Chief Executive Officer of FPC, comments:

"FPC is the leading global supplier of capacitive touch fingerprint sensors and the leading global supplier of fingerprint sensors in mobile phones and tablets. By combining these strengths, FPC has developed the most attractive mobile touch fingerprint sensor on the planet. It is with great pride that we announce a follow-up order for the ramp so soon after the first purchase order for the FPC 1020 related to a smartphone and with a Global Tier 1 player, on track for a timely launch. FPC's superior fingerprint technology, image quality and low power consumption have distanced FPC from any competition for touch sensors in mobile devices such as smartphones and tablets."

*FPC definition of Design Win (DW): The decision by a device vendor (OEM or ODM) to start development of one or several commercial product(s) incorporating FPC's technology into such new product(s).

About Fingerprint Cards AB (publ)

Fingerprint Cards AB (FPC) markets, develops and produces biometric components and technologies that through the analysis and matching of an individual's unique fingerprint verify the person's identity. The technology consists of biometric sensors, processors, algorithms and modules that can be used separately or in combination with each other. The competitive advantages offered by the FPC's technology include unique image quality, extreme robustness, low power consumption and complete biometric systems. With these advantages and the ability to achieve extremely low manufacturing costs, the technology can be implemented in volume products such as smart cards and mobile phones, where extremely rigorous demands are placed on such characteristics. The company's technology can also be used in IT and Internet security, access control, etc.

Fingerprint Cards AB (publ) discloses this information pursuant to the Swedish Securities Market Act (2007:528) and the Swedish Financial Instruments Trading Act (1991:980). The information was issued for publication on May 05, 2014 at 08.00 am CET.

Important information

Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the constituent information in accordance with the rules and regulations prevailing in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any of the company's securities in any jurisdiction.

For more information contact:

Johan Carlstr?m, CEO Fingerprint Cards AB (publ), +46(0)31-60-78-20, investrel@fingerprints.com

SOURCE Fingerprint Cards AB

reade more...

NexID Receives Grants to Fund Further Development, Commercialization of Biometric 'Liveness Detection'

POTSDAM, N.Y., April 30, 2014 /PRNewswire/ -- NexID Biometrics LLC, whose "liveness detection" technology boosts protection in applications with critical security-authentication needs, today announced it has received a series of funding grants totaling $325,000, including a highly competitive award given to emerging companies in central New York state.

NexID, the first company to offer liveness detection software for fingerprint-sensors on mobile devices, said the grants will fund further research, development and commercialization of additional modes of authentication that go beyond its deep expertise in detecting and mitigating attempts to spoof fingerprint scanners used for authenticating entry to secure locations and systems.

NexID will participate with Clarkson University here and West Virginia University in the joint research into biometric security technology sponsored by the National Science Foundation and gain the right to license technology that results from that research. NexID is a venture "spinout" from both institutions, with several of the company's founders serving on their faculty.

To expand the NSF-funded work at Clarkson and WVU, NexID has received a matching grant of $100,000 from Seaway Private Equity Corporation (SPEC) to develop a commercial liveness-detection application for security systems that scan people's faces and the irises in human eyes. SPEC provides early stage equity capital funding for companies in St. Lawrence County, N.Y., with significant growth potential.

NexID also received a $150,000 Grant for Growth from the Syracuse-based CenterState Corporation for Economic Opportunity (CEO), which will be augmented by another matching grant from SPEC in the amount of $75,000. The CenterState CEO grant to NexID was one of only two organizations awarded from among scores of companies that applied for funding.

"We expect this funding to extend and accelerate our operations through the two to three years it may take before NexID begins to realize royalty revenue from the licensing of our technology in these new areas," said Dr. Stephanie Schuckers, Professor of Electrical and Computer Engineering at Clarkson University and CEO of NexID.

Privately held, NexID has operated organically since 2007 by licensing the use of its software to makers of traditional fingerprint-scanning systems to authenticate users at international border crossings and to gain access to laptops, systems and secure locations. NexID's research into spoofing techniques and liveness detection software raises the effectiveness of fingerprint-scanning systems to over 95 percent.

The introduction of fingerprint scanning in popular smartphones, such as Apple's iPhone 5S with TouchID and Samsung's Galaxy S® 5, has caused the market for scanner-equipped mobile devices – and the need to safeguard them from spoofing -- to explode. Meanwhile, heightened concerns for security around the world are driving global demand for additional modes of biometric authentication.

"We're proud of the renowned expertise in biometrics and cyber security that Dr. Schuckers and NexID bring to Clarkson," said University President Anthony Collins, Ph. D. "It's an honor for our institution to be associated so closely with their leadership in this highly specialized area.

"Further, as a member of the Seaway Private Equity Corporation's Board of Directors, I'm pleased to see that NexID, truly a global center of excellence in biometrics technology here in the northern New York region, is receiving matching funds to further leverage this opportunity for growth," Collins said.

About NexID Biometrics
NexID Biometrics is a leading software and technology supplier to the biometric-authentication industry. The company develops and licenses liveness detection software that enables fingerprint-scanning technologies to more accurately, and with greater confidence, authenticate scanned images by mitigating spoof-related risks. The company also provides testing and analysis of fingerprint scanning devices to identify existing vulnerabilities to known spoofing strategies. The company's founders represent some of the world's leading authorities on biometric spoof mitigation and liveness detection.

Logo - http://photos.prnewswire.com/prnh/20131016/SF97206LOGO

SOURCE NexID

RELATED LINKS
http://www.nexidbiometrics.com

reade more...

SBH Diagnostics receives High-Complexity-CLIA Certification at Natick, Massachusetts Lab

BOSTON, March 4, 2014 /PRNewswire-iReach/ -- (Natick, MA) January 19, 2014. SBH Diagnostics announced receipt for CLIA certification and will offer the highly anticipated Picosensitive C-Peptide and Glucagon Assays in the US and Canada for diagnostic testing.

C-peptide has been used as a surrogate marker for insulin secretion in research and clinical diagnostics for many years.

The Picosensitive Assay called CPEP3, (exclusive Diagnostic-Use license from Mercodia, SA), is highly specific, precise and offers a low measuring range, not available with any other C-peptide assay on the market today. This assay allows many diabetic patients who may have been characterized as C-peptide negative based on the use of standard (less sensitive) methods to have their C-peptide levels accurately measured and this knowledge may affect treatment plans, inclusion in clinical trials, etc.

The value of this C-peptide assay has been highlighted by various groups including AACC publications (Clinical Laboratory News and Clinical Laboratory Strategies) and several publications by the Faustman Lab at MGH. The Pico Assay not only has important potential implications for patients and clinicians, it also allows for changes in inclusion criteria and monitoring during trials that assess treatments targeting those with long-term type 1 diabetes. This can also lead to intervention therapies to mitigate diabetes complications.

SBH Diagnostics will include the Picosensitive Assay in their CLIA Lab test portfolio, making it available to clinicians, in addition to those conducting clinical trials and companies involved with diabetes diagnosis, management and therapeutics.

"With CLIA certification, SBH Diagnostics now has the capacity to provide comprehensive solutions for clients working in clinical environments," stated Raphael Nir, President, SBH Diagnostics, Inc. "We are committed to providing clinical researchers, physicians, and patients with C-peptide testing results that ultimately lead to better diagnoses and more effective treatments. Because we deliver validated tests through our own CLIA laboratory, our partners have the ability to test clinical samples in a CLIA-certified setting, with appropriate standard operating procedures, Quality Management Systems, and robust documentation. The company's laboratory operates under Good Laboratory Practice, and all personnel follow strict confidentiality guidelines and undergo a rigorous training program including Health Insurance Portablilty and Accountability Act (HIPAA) practices".

SBH Diagnostics (SBHD) is an innovative Contract Research Organization and CLIA Lab dedicated to providing accurate and reproducible biomarker analysis services. We are focused on the commercialization of Laboratory Developed Tests (LDTs). In the SBH Diagnostics portfolio under CLIA auspices are the Pico-molar C-Peptide test, the highly-specific Glucagon Test and the EASy-Sjogren's test using the Automatic Simple Western process. SBHD is located in Natick, MA and is associated with SBH Sciences and GlycoZym.

Mercodia AB is a Swedish biotech company focusing on the development of high quality immunoassays within the field of metabolic disorders. Mercodia is a world-leading supplier to all major international markets and provides a professional scientific support system to develop novel applications for existing products and unique diagnostics for emerging markets. Mercodia has demonstrated compliance with "International Organization for Standardization (ISO) in 13485:2003, Medical Devices – Quality Management Systems – Requirements for Regulatory Purposes".

For further information, please contact:
Marvin A. Collin, Vice President
SBH Diagnostics
617-680-9792
macollin@sbhdiagnostics.com
www.sbhdiagnostics.com

Media Contact: Raphael Nir, SBH Diagnostics, 5086506218 Ext. 214, rnir@sbhsciences.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE SBH Diagnostics

RELATED LINKS
http://www.sbhdiagnostics.com

reade more...

Hole Labs receives Envisioneering innovation & Prize design in the 2014 ShowStoppers at the Consumer Electronics Show

LAS VEGAS, 10 January 2014/PRNewswire /-Eureka Hall, The Venetian / Booth #75006 - the era of passwords is finally again and everything so you have to log in to social media profiles, perform transactions and sign on the bank account is your biometric data and smartphone. In ShowStoppers this year at the Consumer Electronics Show (CES), pits Labs, a digital infrastructure company, received the award for innovation & design Envisioneering application recently launched HoyosID.

This new platform of assertion of identity is a free, easy to use and practically can hack iPhone and Android app that uses a system of biometric recognition multi - including face, iris and periocular region - to confirm the identity, with a single component "liveness" to distinguish between a living person from a picture or video.

End-to-end technology aims to protect consumers and businesses through the use of devices like smartphones pattern of acquisition of biometric data in real time - without additional takeaway - hardware and mobile user authentication from a browser and password and fields on mobile devices without cost to users.

"My team is an honor having been recognized by ShowStoppers at CES for the launch of HoyosID, our new platform for assertion of identity," said Hector Hoyos, CEO and founder of the laboratories of holes. "For years, we have collectively worked to combine our knowledge and experience in the fields of technology and biometric data to create an attractive product that would ensure the material of individuals and companies in a convenient and cost effective way, without people having to carry an additional device to keep personal information secure."

"People are starting to realize that we need a better system in place to keep the material private protected and user names, passwords, and access are, no doubt not the solution - that we have failed many times and are so vulnerable to guards", said Hoyos. "Imagine a world in which we all need access to our personal accounts on the Internet is our face and a smartphone - without additional tabs - has become a reality, and we are eager to expand the applications of this technology further in the financial services space."

Hole Labs is led by Hector Hoyos, whose defense and security products have helped protect lives and properties for decades. In addition to holding several patents, he also invented the HBOX and EyeSwipe biometric authentication identity technologies and founded Global makers, Inc. (later renamed EyeLock Corp.).

For more information about pits and HoyosID laboratories, please visit: www.hoyoslabs.com. The application will be available for download later this quarter.

About hole Labs
Hole Labs is a company of security of digital infrastructure with security, computer vision and biometrics and big data experts. Hole Labs aims to develop and implement the company and the consumer identity assertion technology platforms that address conveniently and safely identity challenges claim today. Hole laboratories currently has offices in New York, Boston, Bucharest (Romania) and Beijing (China).

Media contacts:
Samantha Wolf / Caitlin Kasunich
The radio station KCSA Strategic Communications
swolf@KCSA.com / ckasunich@kcsa.com
212-896-1220 / 212-896-1241

SOURCE pits Labs

Hoyos Labs Receives Envisioneering Innovation & Design Award at the 2014 ShowStoppers at the Consumer Electronics Show

LAS VEGAS, Jan. 10, 2014 /PRNewswire/ -- Eureka Hall, The Venetian / Booth #75006 -- The era of usernames and passwords is finally over, and all one will need to log onto social media profiles, conduct transactions and sign into banking account are his or her biometrics and smartphone. At this year's ShowStoppers at the Consumer Electronics Show (CES), Hoyos Labs, a digital infrastructure company, received the Envisioneering Innovation & Design Award for its recently launched app, HoyosID.

This new identity assertion platform is a free, easy-to-use and virtually unhackable iPhone and Android app that uses a multi-biometric recognition system – including the face, iris and periocular region – to confirm one's identity, with a unique "liveness" component to distinguish a living person from a photograph or video.

The end-to-end technology aims to protect both consumers and corporations by leveraging smartphones as real-time biometrics pattern acquisition devices – with no need for additional hardware to carry – and moving authentication out of a browser's username and password fields and onto mobile devices at no cost to users.

"My team is honored to have been recognized by ShowStoppers at CES for the launch of HoyosID, our new identity assertion platform," said Hector Hoyos, CEO and founder of Hoyos Labs. "For years, we have collectively worked to combine our knowledge and expertise in the biometrics, IT and technology fields to create an attractive product that would secure the material of both individuals and companies in a convenient and cost-effective way, without requiring people to carry around an additional gadget to keep personal information safe."

"People are beginning to realize that we need a better system in place to keep our private material protected, and usernames, passwords and log-ins are, without a doubt, not the solution – they have failed us all too many times and are so vulnerable to hacks," Hoyos added. "Imagining a world in which all we need to access our personal accounts on the Internet is our face and a smartphone – no additional tokens – has now become a reality, and we are eager to expand the applications of this technology further into the financial services space."

Hoyos Labs is led by Hector Hoyos, whose security and defense products have helped to protect lives and properties for decades. In addition to holding multiple patents, he also invented the HBOX and EyeSwipe biometrics identity authentication technologies and founded Global Rainmakers, Inc. (later renamed EyeLock Corp.).

For more information on Hoyos Labs and HoyosID, please visit: www.hoyoslabs.com. The app will be available for download later this quarter.

About Hoyos Labs
Hoyos Labs is a digital infrastructure security company with security, computer vision and biometrics and big data experts. The goal of Hoyos Labs is to develop and deploy enterprise and consumer identity assertion technology platforms that will conveniently and securely address the identity assertion challenges of today. Hoyos Labs currently has offices in New York, Boston, Bucharest (Romania) and Beijing (China).

Media Contacts:
Samantha Wolf / Caitlin Kasunich
KCSA Strategic Communications
swolf@kcsa.com / ckasunich@kcsa.com
212-896-1220 / 212-896-1241

SOURCE Hoyos Labs

Hoyos Labs Receives Envisioneering Innovation & Design Award at the 2014 ShowStoppers at the Consumer Electronics Show

For more information on Hoyos Labs and HoyosID, please visit: www.hoyoslabs.com. The app will be available for download later this quarter.

Media Contacts:
Samantha Wolf / Caitlin Kasunich
KCSA Strategic Communications
swolf@kcsa.com / ckasunich@kcsa.com
212-896-1220 / 212-896-1241

SOURCE Hoyos Labs

Inovio Pharmaceuticals CEO Receives 2013 Drug Discovery & Achievement Award

Inovio Pharmaceuticals, Inc. (PRNewsFoto/Inovio Pharmaceuticals, Inc.)jwplayer.key="2kY/GKwZ2uQZmDlQ9VYArfZt2b4+KhHX3+DM4zisgtE=";BLUE BELL, Pa., Nov. 14, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that its President & CEO, Dr. J. Joseph Kim, has been selected to receive the 2013 Achievement in Drug Discovery and Development Award from the Korean American Society in Biotech and Pharmaceuticals ("KASBP"). The Society aims to contribute to the growth of drug discovery and development through collaborations and information exchanges between U.S. and Korean pharmaceutical companies and research centers.

The award, sponsored by Daewoong Pharmaceuticals Inc., the leading Korean pharmaceutical company, recognizes Dr. Kim as one of the leaders in moving the field of DNA vaccines from theory to application and development. Dr. Kim founded VGX Pharmaceuticals, which through acquisition became Inovio, and is the leading biotech company advancing DNA vaccines toward commercialization. Inovio is revolutionizing vaccines and immunotherapies to prevent and treat cancers and challenging infectious diseases with products in Phase II development.

Jae-Hun Kim, Ph.D. of Merck Research Laboratories, the current KASBP President, said, "We are very pleased to present the award to Dr. Joseph Kim. The award committee recognized Dr. Kim's significant achievement for invention and development of the technology as a scientist and as a businessman."

Dr. J. Joseph Kim, President & CEO of Inovio Pharmaceuticals said, "This honor recognizes the work of countless scientists who, like me, have pursued the potential of DNA vaccines because we understand the paradigm-changing contribution that DNA vaccines will make to human health. At Inovio, we've shown clinical results that no other organization can match in generating T cells. We believe this technology will change the practice of medicine in treating cancer, HIV, hepatitis, malaria and other infectious diseases. I thank KASBP for this award and for their tireless work in building a bridge between the U.S. and Korea with a goal to advance drug discovery and development."

About the Korean American Society in Biotech and Pharmaceuticals ("KASBP")

The Korean American Society in Biotech and Pharmaceuticals ("KASBP") is a non-profit organization founded in May 2001. The current members include Korean-American professionals working throughout the U.S., mostly in the Biotech or Pharmaceutical field. The member profile includes not only professionals working in 100 pharmaceutical industries (BMS, Novartis, GSK, Merck, Sanofi, J&J, Pfizer, etc.), but also scientists in academics serving universities as faculty members, researchers, post-docs, or graduate students; as well as government employees in the FDA, NIH, and other local and federal government organizations.

KASBP aims to promote scientific recognitions in the community, especially for drug discovery and development. KASBP's activities include annual symposiums to contribute to the advancement of drug discovery, development and other pharmaceutical technology in Korean and U.S. companies. Through a collaboration and networking among the members in Biotech companies, pharmaceutical companies and government funded research centers; KASBP has been helping new drug discovery, technology transfer, drug development and commercialization by Korean companies in Korea and in the U.S markets. One important goal of KASBP is to identify and nurture young Korean-American researchers to become future leaders for Biotech and Pharmaceutical industries in Korea and the U.S. by awarding scholarships.

About Inovio Pharmaceuticals, Inc.

Inovio is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon® vaccines, in combination with its proprietary electroporation delivery, are generating best-in-class immune responses, with therapeutic T-cell responses exceeding other technologies in terms of magnitude, breadth, and response rate. Human data to date have shown a favorable safety profile. Inovio's lead vaccine, a therapeutic against HPV-caused pre-cancers and cancers, is in phase II. Other phase I and preclinical programs target prostate, breast, and lung cancers as well as HIV, influenza, malaria and hepatitis. Partners and collaborators include Roche, the University of Pennsylvania, Merck, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, University of Southampton, US Dept. of Homeland Security, University of Manitoba and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2012, our Form 10-Q for the quarter ended September 30, 2013, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

CONTACTS:
Investors: Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101 bhertel@inovio.com
Media: Jeff Richardson, Inovio Pharmaceuticals, 267-440-4211, jrichardson@inovio.com

(Logo: http://photos.prnewswire.com/prnh/20120131/LA44118LOGO)

SOURCE Inovio Pharmaceuticals, Inc.

Regulus Demonstrates Initial Progress in microRNA Biomarkers MS Collaboration and Receives Milestone Payment from Biogen Idec

LA JOLLA, Calif., Nov. 20, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has demonstrated initial progress in its research collaboration with Biogen Idec, M.A. ("Biogen Idec") to discover microRNAs as biomarkers for multiple sclerosis ("MS") and has received a milestone payment.

Regulus has developed a highly reproducible, proprietary platform for extracting, profiling, and analyzing microRNAs from small volumes of serum. Under its collaboration with Biogen Idec, Regulus applied this platform to profile over 400 serum samples from MS patients and compared these samples against those from healthy volunteers in the largest known MS serum profiling experiment performed to date. The results of this large and successful experiment have provided the foundation for identifying potential biomarker signatures for patients with MS. Based on the initial progress, Regulus and Biogen Idec will now work on the next phase of the research collaboration to validate further the microRNA biomarker signatures in patients with relapse-remitting MS, the most common form of the disease.

"We are very excited about our early success in this collaboration and are hopeful that our efforts advance Biogen Idec's work in treating MS," said Neil W. Gibson, Ph.D., Chief Scientific Officer of Regulus. "Further, we believe that achievement of this milestone assigns significant value to our proprietary technology and demonstrates the potential of our emerging biomarkers platform to support our microRNA therapeutic pipeline." Regulus believes that microRNA biomarkers may be used to select optimal patient segments in clinical trials, to develop companion diagnostics, and to monitor disease progression or relapse.

In August 2012, Regulus entered into a research collaboration with Biogen Idec to explore microRNAs as biomarkers for disease monitoring and response to therapy. In June 2013, Regulus and Biogen Idec amended the collaboration agreement to update the research plan and criteria for success. The collaboration is initially focused on the discovery of microRNAs as biomarkers for MS. Under the transaction, Regulus has received an upfront payment and has earned an initial milestone payment and is also eligible to receive additional milestone payments. Additionally, Biogen Idec made an investment in Regulus in the form of a promissory note that converted into shares of Regulus' common stock upon the closing of the Company's initial public offering in October 2012.

About microRNAs and microRNAs as Biomarkers

The discovery of microRNAs in humans during the last decade is one of the most exciting scientific breakthroughs in recent history. microRNAs are small RNA molecules, typically 20 to 25 nucleotides in length, that do not encode proteins but instead regulate gene expression. More than 500 microRNAs have been identified in the human genome, and over one-third of all human genes are believed to be regulated by microRNAs. microRNA expression, or function, has been shown to be significantly altered or dysregulated in many disease states, including oncology, fibrosis and metabolic diseases. Regulus believes that microRNAs are clinically relevant therapeutic targets and may be ideally suited as biomarkers for these disease states and others, like MS.

microRNAs have been detected in bodily fluids such as blood, and emerging data has demonstrated that microRNA signatures in blood can mimic the expression profile observed in disease tissues. Regulus has a comprehensive intellectual property estate and oligonucleotide technology know-how and believes that microRNA biomarkers may be used to select optimal patient segments in clinical trials, to develop companion diagnostics, and to monitor disease progression or relapse.

About Regulus

Regulus Therapeutics Inc. (NASDAQ: RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus is uniquely positioned to leverage a mature therapeutic platform that harnesses the oligonucleotide drug discovery and development expertise of Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc., which founded the company. Regulus has a well-balanced microRNA therapeutic pipeline entering clinical development, an emerging microRNA biomarkers platform to support its therapeutic programs, and a rich intellectual property estate to retain its leadership in the microRNA field. Regulus intends to focus its proprietary efforts on developing microRNA therapeutics for oncology indications and orphan diseases and is currently advancing several programs toward clinical development in oncology, fibrosis and metabolic diseases. Regulus is also developing RG-101, a GalNAc-conjugated anti-miR targeting microRNA-122, for the treatment of chronic hepatitis C virus infection. Regulus' commitment to innovation and its leadership in the microRNA field have enabled the formation of strategic alliances with AstraZeneca, GlaxoSmithKline and Sanofi. In addition, Regulus has formed a research collaboration with Biogen Idec around its emerging microRNA biomarkers platform.

For more information, please visit http://www.regulusrx.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with Regulus' expectations regarding future therapeutic and commercial potential of Regulus' business plans, technologies and intellectual property related to microRNA therapeutics being discovered and developed by Regulus. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Regulus' current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Regulus' programs are described in additional detail in Regulus' SEC filings. All forward-looking statements contained in this press release speak only as of the date on which they were made. Regulus undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

SOURCE Regulus Therapeutics Inc.

Pages

.